People · Operator
Named in public records as an officer, director or promoter · active 2008–2018 · Other Health Care, Pharmaceuticals, Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| HistoSonics, Inc. | — | Other Health Care | Series D+ | $308.2M | $1.0B | 2018 |
| PhaseBio Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $102.1M | $912.3M | 2018 |
| Juventas Therapeutics Inc | — | Biotechnology | Series B | $35.8M | $52.0M | 2008 |
| Swift Biosciences, Inc. | — | Biotech / Pharma | Series A | $31.5M | $134.0M | 2018 |
| SironRX Therapeutics, Inc. | — | Other Health Care | Seed | $5.7M | $84.6M | 2011 |
Linda Tufts at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Linda Tufts on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Emont | 2 | 4 |
| Rahul Aras | 2 | 3 |
| Somu Subramaniam | 1 | 17 |
| Mark Lewis | 1 | 15 |
| Jack Ball | 1 | 10 |
| Clay Thorp | 1 | 10 |
| Dan Watkins | 1 | 8 |
| George Arida | 1 | 6 |
| Justin Klein | 1 | 6 |
| Tyrell Rivers | 1 | 6 |
| V. Kadir Kadhiresan | 1 | 5 |
| JAMES ADOX | 1 | 5 |
| Jon Freeman | 1 | 5 |
| Gerry Brunk | 1 | 5 |
| Roger Newton | 1 | 4 |
| Marc Penn | 1 | 4 |
| Kadir Kadhiresan | 1 | 4 |
| Michael Blue | 1 | 4 |
| Dan Kidle | 1 | 4 |
| Christopher Prior | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.